Tuesday, July 16, 2019

Trefoil Therapeutics Raises $28M

San Diego-based Trefoil Therapeutics, which is developing treatments for corneal diseases, has raised $28M in its Series A funding, the company said on Tuesday. According to the company, the funding was led by Bios Partners, and also included Access Biotechnology, plus Hatteras Venture Partners, Aju IB Investment, Correlation Ventures, ExSight Ventures and InFocus Capital Partners. As part of the funding, Bios Partners' co-founder Stella M. Robertson, Ph.D., joins the company's board; Robertson was formerly vice president in Research & Development at Alcon Laboratories. Trefoil Therapeutics says it is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders.